Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis

N Ruperto; DJ Lovell; A Reiff; M Gamir; G Higgins; I Koné-Paut; OY Jones; E Chalom; N Ilowite; C Wouters; MJ McIlraith; S Liu; H Kupper; EH Giannini; A Martini

Journal ArticleOPEN ACCESS

Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis

Ruperto N
Lovell D
Reiff A
et al.

Pediatric Rheumatology (2011) 9(S1)

DOI: 10.1186/1546-0096-9-s1-o26

N/ACitations

15Readers

Abstract

Long-term efficacy and safety of adalimumab in ... N Ruperto1*, DJ Lovell2, A Reiff2, M Gamir1, G Higgins2, I Kon{é}-Paut1, OY Jones2, E Chalom2, N Ilowite2, C Wouters1, MJ McIlraith3, S Liu4, H Kupper5, EH Giannini2, A Martini1

Cite

CITATION STYLE

APA

Ruperto, N., Lovell, D., Reiff, A., Gamir, M., Higgins, G., Koné-Paut, I., … Martini, A. (2011). Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis. Pediatric Rheumatology, 9(S1). https://doi.org/10.1186/1546-0096-9-s1-o26

Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis

Abstract

Cite

Register to see more suggestions